Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Auxilium" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Auxilium for you to read. Along with our medical data and news we also list Auxilium Clinical Trials, which are updated daily. BioPortfolio also has a large database of Auxilium Companies for you to search.
Auxilium Pharmaceuticals and Alimera Sciences are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability. This is a breakdown of current ratings and recommmendations for Auxilium Pharmaceuticals and Alimera Sciences, as...
Fortress Biotech and Auxilium Pharmaceuticals are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. This is a breakdown of current ratings and price targets for Fortress Biotech and Auxilium Pharmaceuticals, as report...
NEW YORK: A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks.
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its board of directors has appointed Dr. Philippe Chambon as a new, independent, non-executive member. He i...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Andrew I. Koven to the Company’s Board of Directors. Mr. Koven will serve as a Class I director and serve on the ...
Completed Initial Public Offering Raising $103.5 million in gross proceeds Submitted New Drug Application to U.S. Food and Drug Administration for INVELTYS™ (KPI-121 1%) Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary muc...